• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A DNA vaccine that targets hemagglutinin to antigen presenting cells protects mice against H7 influenza.

tetano

Editor, Senior Moderator
J Virol. 2017 Sep 20. pii: JVI.01340-17. doi: 10.1128/JVI.01340-17. [Epub ahead of print]
[h=1]A DNA vaccine that targets hemagglutinin to antigen presenting cells protects mice against H7 influenza.[/h] Andersen TK[SUP]1,[/SUP][SUP]1[/SUP], Zhou F[SUP]1,[/SUP][SUP]2[/SUP], Cox R[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Bogen B[SUP]1,[/SUP][SUP]1,[/SUP][SUP]4[/SUP], Gr?deland G[SUP]5,[/SUP][SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Zoonotic influenza H7 viral infections have a case fatality rate of about 40%. Currently no or limited human to human spread has occurred, but we may be facing a severe pandemic threat if the virus acquires the ability to transmit between humans. Novel vaccines that can be rapidly produced for global distribution are urgently needed, and DNA vaccines may be the only type of vaccine that allows for the speed necessary to quench an emerging pandemic. Here, we have constructed DNA vaccines encoding the hemagglutinin (HA) from influenza A/chicken/Italy/13474/99 (H7N1). In order to increase the efficacy of DNA vaccination, HA was targeted to either major histocompatibility complex (MHC) class II molecules or chemokine receptors 1, 3 and 5 (CCR1/3/5) that are expressed on antigen presenting cells (APC). A single DNA vaccination with APC-targeted HA significantly increased antibody levels in sera, as compared to non-targeted control vaccines. The antibodies were confirmed neutralizing in an H7 pseudotype-based neutralization assay. Furthermore, the APC-targeted vaccines increased the levels of antigen-specific cytotoxic T-cells, and a single DNA vaccination could confer protection against a lethal challenge with influenza A/turkey/Italy/3889/1999 (H7N1) in mice. In conclusion, we have developed a vaccine that rapidly could contribute protection against a pandemic threat from avian influenza.IMPORTANCE: Highly pathogenic avian influenza H7 constitute a pandemic threat that can cause severe illness and death in infected individuals. Vaccination is the main method of prophylaxis against influenza, but current vaccine strategies fall short in a pandemic situation due to a prolonged production time and insufficient production capabilities. In contrast, a DNA vaccine can be rapidly produced and deployed to prevent the potential escalation of a highly pathogenic influenza pandemic. We here demonstrate that a single DNA delivery of hemagglutinin from an H7 influenza could mediate full protection against a lethal challenge with H7N1 influenza in mice. Vaccine efficacy was contingent on targeting of the secreted vaccine protein to antigen presenting cells.
Copyright ? 2017 Andersen et al.


PMID: 28931687 DOI: 10.1128/JVI.01340-17
 
Back
Top Bottom